ANXA2 and cancer: In conclusion, here we show that a prototype peptide such as cell-internalizing LGRFYAASG-pen mechanistically interferes with intracellular annexin A2, representing a multifaceted inhibitor of cytoskeletal arrangements pivotal for key steps in cancer progression in preclinical tumor models.